THE ROLE OF TUMOR-NECROSIS-FACTOR IN ALLOGRAFT-REJECTION .2. EVIDENCE THAT ANTIBODY THERAPY AGAINST TUMOR NECROSIS FACTOR-ALPHA AND LYMPHOTOXIN ENHANCES CARDIAC ALLOGRAFT SURVIVAL IN RATS

被引:75
作者
IMAGAWA, DK
MILLIS, JM
OLTHOFF, KM
SEU, P
DEMPSEY, RA
HART, J
TERASAKI, PI
WASEF, EM
BUSUTTIL, RW
机构
[1] UNIV CALIF LOS ANGELES,SCH MED,DEPT SURG,LIVER TRANSPLANT PROGRAM,10833 LECONTE,LOS ANGELES,CA 90024
[2] UNIV CALIF LOS ANGELES,SCH MED,DEPT PATHOL,LOS ANGELES,CA 90024
[3] UNIV CALIF LOS ANGELES,TISSUE TYPING LAB,LOS ANGELES,CA 90024
[4] ENDOGEN CORP,BOSTON,MA
关键词
D O I
10.1097/00007890-199008000-00003
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In the previous study we demonstrated that circulating levels of TNF-α are elevated during liver allograft rejection and may precede clinical manifestations. The current study was designed to investigate the efficacy of antibody therapy against tumor necrosis factor-alpha and lymphotoxin (LT) in a rat heterotopic cardiac transplant model utilizing Buffalo donors and Lewis recipients. Control animals received no immunotherapy and experienced rejection on postoperative day 11 ± 0.4 (mean ± SEM). Experimental animals received immunotherapy either intraperitoneal or intravenous from days 1 to 10. The i.p. administered anti-TNF-α prolonged graft survival to 16 ± 2.7 days (P < 0.05 vs. controls); the i.v. administration prolonged survival to 15 ± 1.4 days (P < 0.004). Animals treated with i.p. anti-LT survived 17 ± 1.7 days (P < 0.002 vs. controls). Combination immunotherapy of anti-TNF-α and anti-LT increased function to 21 ± 2.2 days (P < 0.001 vs. controls). Conversely, administration of purified TNF-α or LT to graft recipients accelerated the time to rejection. Mean survival for both treatments was 7 days (P < 0.001 vs. controls). Histologic examination of the transplanted cardiac tissue showed a typical pattern for acute rejection; there was no evidence of hemorrhagic or coagulative necrosis. In contrast, administration of purified TNF-α or LT to recipients of a syngeneic heart did not stimulate rejection. These data suggest that TNF-α and LT may play a role in the pathogenesis of acute allograft rejection. In addition, the mechanism appears to be distinct from that seen in TNF-α or LT-mediated cytotoxicity of tumor cells.
引用
收藏
页码:189 / 193
页数:5
相关论文
共 23 条
[11]  
KAYE J, 1984, J IMMUNOL, V133, P1339
[12]   IMMUNE-MECHANISMS IN ORGAN ALLOGRAFT-REJECTION .6. DELAYED-TYPE HYPERSENSITIVITY AND LYMPHOTOXIN IN EXPERIMENTAL RENAL-ALLOGRAFT REJECTION [J].
LOWRY, RP ;
MARGHESCO, DM ;
BLACKBURN, JH .
TRANSPLANTATION, 1985, 40 (02) :183-188
[13]  
LOWRY RP, 1988, TRANSPLANT P, V20, P245
[14]   RAISED SERUM LEVELS OF CACHECTIN/TUMOR NECROSIS FACTOR-ALPHA IN RENAL-ALLOGRAFT REJECTION [J].
MAURY, CPJ ;
TEPPO, AM .
JOURNAL OF EXPERIMENTAL MEDICINE, 1987, 166 (04) :1132-1137
[15]   DEMONSTRATION OF ALPHA-LYMPHOTOXIN IN HUMAN REJECTED RENAL-ALLOGRAFTS [J].
MOY, J ;
ROSENAU, W .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1981, 20 (01) :49-56
[16]   IMPROVED TECHNIQUE OF HEART TRANSPLANTATION IN RATS [J].
ONO, K ;
LINDSEY, ES .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1969, 57 (02) :225-+
[17]   HUMAN-TUMOR NECROSIS FACTOR - PRECURSOR STRUCTURE, EXPRESSION AND HOMOLOGY TO LYMPHOTOXIN [J].
PENNICA, D ;
NEDWIN, GE ;
HAYFLICK, JS ;
SEEBURG, PH ;
DERYNCK, R ;
PALLADINO, MA ;
KOHR, WJ ;
AGGARWAL, BB ;
GOEDDEL, DV .
NATURE, 1984, 312 (5996) :724-729
[18]  
POBER JS, 1989, TUMOR NECROSIS FACTO, V134, P551
[19]   INHIBITION OF CYTOTOXIC T-CELL DEVELOPMENT BY TRANSFORMING GROWTH-FACTOR-BETA AND REVERSAL BY RECOMBINANT TUMOR-NECROSIS-FACTOR-ALPHA [J].
RANGES, GE ;
FIGARI, IS ;
ESPEVIK, T ;
PALLADINO, MA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1987, 166 (04) :991-998
[20]  
SCHEURICH P, 1987, J IMMUNOL, V138, P1786